Apollomics Advances c-MET Inhibitor Vebreltinib Toward FDA Submission Following Strategic Turnaround
核心洞察
Apollomics plans to submit an Investigational New Drug Application for accelerated approval of vebreltinib for second-line NSCLC treatment with c-MET (搜索) amplification in the first half of 2027, based on FDA guidance.
The company's lead asset vebreltinib has already received approval in China for three indications including METex14 skipping NSCLC and MET-amplified NSCLC, marking it as the first c-MET (搜索) inhibitor approved for certain conditions.
Following a strategic turnaround with new management, Apollomics reduced operating expenses by 64% year-over-year to $19.8 million in 2025 while advancing global Phase 2 studies with over 282 subjects enrolled.
Apollomics Inc. is positioning its lead c-MET (搜索) inhibitor vebreltinib for potential accelerated approval in the United States, with plans to submit an Investigational New Drug Application for second-line treatment of non-small cell lung cancer (NSCLC) patients with c-MET amplification in the first half of 2027. The submission timeline is based on guidance from the U.S. Food and Drug Administration, according to the company's announcement of its full-year 2025 financial results.
Clinical Progress and Regulatory Milestones
Vebreltinib (APL-101) has demonstrated significant clinical progress, with more than 600 patients and 170 healthy volunteers dosed in clinical trials to date. The highly specific, CNS-penetrant c-MET (搜索) inhibitor has already achieved regulatory success in China, where it received approval from the National Medical Products Administration (NMPA) for three distinct indications: METex14 skipping NSCLC, MET-amplified NSCLC, and PTPRZ1-MET (搜索) fusion high-grade gliomas. Notably, vebreltinib is the first c-MET inhibitor approved for the latter two conditions.
The ongoing Phase 2 component of the SPARTA clinical study (APL-101-01) is evaluating vebreltinib's efficacy and safety across multiple solid tumor types. The open-label multi-cohort study is being conducted at approximately 25 study sites in over 10 countries across North America, Europe, and Asia-Pacific, with over 282 subjects enrolled as of April 2026.
Interim efficacy and safety data from both the global multi-cohort Phase 2 SPARTA trial and the multi-cohort Phase 2 KUNPENG trial demonstrated that vebreltinib appeared efficacious in NSCLC patients with MET Exon14 skipping mutation with or without co-occurring MET amplification.
Strategic Partnerships and Global Development
In March 2025, Apollomics entered into a development and commercialization agreement with LaunXP International (搜索) Co., Ltd., granting LaunXP exclusive rights to develop and commercialize vebreltinib in combination with an EGFR (搜索) inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for NSCLC treatment. This partnership generated $8.5 million in revenue for 2025 through an upfront payment, marking the company's first revenue generation compared to zero in 2024.
The company is also preparing for a Phase 2/3 IND submission for vebreltinib development in combination with an EGFR (搜索) inhibitor in the U.S. and select Asian countries for NSCLC treatment, expanding the therapeutic potential of the asset through combination strategies.
Corporate Transformation and Financial Performance
Apollomics underwent significant organizational changes in September 2025 with the appointment of a new management team led by Chief Executive Officer Hung-wen (Howard) Chen, Chief Operating Officer Yi-kuei (Alex) Chen, and Chief Financial Officer Peter Lin. The new leadership has executed a strategic turnaround plan focused on cost reduction and operational streamlining.
"Our primary focus is to advance the global development of vebreltinib for the treatment of patients with c-MET (搜索) alterations across different tumors," said Chen.
The company achieved substantial cost reductions in 2025, with operating expenses decreasing 64% year-over-year to $19.8 million compared to $55.7 million in 2024. Research and development expenses dropped to approximately $5.5 million from $24.6 million, while general and administrative expenses decreased to $12.4 million from $17.8 million.
Net loss for 2025 was $10.9 million, or $7.57 per diluted share, representing a significant improvement from the $53.9 million net loss, or $52.80 per diluted share, recorded in 2024. Cash and cash equivalents totaled approximately $3.3 million as of December 31, 2025, supported by a $4.1 million private investment in public equity financing completed in September 2025.
Immuno-Oncology Pipeline
Beyond vebreltinib, Apollomics maintains a portfolio of immuno-oncology candidates. APL-501, an investigational humanized IgG4 monoclonal antibody targeting PD-1 (搜索), is undergoing Phase 1 evaluation in advanced or relapsed/refractory solid tumors in Australia, with data currently being analyzed.
APL-502 (benmelstobart), a novel IgG1 humanized monoclonal antibody against PD-L1 (搜索), has achieved regulatory approval in China under the designation TQB-2450 for three indications: extensive-stage small cell lung cancer, recurrent/metastatic endometrial cancer, and late-stage unresectable or metastatic renal cell carcinoma. Ongoing clinical trials are evaluating APL-502 across multiple tumor types including NSCLC, esophageal cancer, ovarian cancer, hepatocellular carcinoma, cholangiocarcinoma, primary mediastinal large B cell lymphoma, and alveolar soft part sarcoma.
The company has strategically out-licensed China rights for both APL-501 and APL-502 to regional partners while retaining global ex-China rights, allowing for focused development resources on international markets while maintaining revenue potential through partnership agreements.